Skip to Content
Morningstar

Kenvue Inc KVUE

Morningstar Rating
Unlock
Stock XNYS Rating as of
$20.54 +0.09 (0.44%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Kenvue Earnings: Soft Start to 2024 but Margins Shine and Full-Year Recovery Intact; Shares Cheap

Keonhee Kim

Wide-moat Kenvue reported mixed first-quarter results that were largely in line with our expectations. Total sales of $3.9 billion were up 1.1% year over year as moderate pricing and a strong demand environment in Europe, Middle East, and Africa and Latin America offset overall weak volume. We maintain our fair value estimate of $25.50 per share, as minor adjustments to our near-term assumptions were immaterial to the valuation.

Read Full Report

Price vs Fair Value

View History
KVUE is trading at a 634% premium.
Price
$20.45
Fair Value
$69.60
Uncertainty
Medium
1-Star Price
$23.75
5-Star Price
$77.36
Economic Moat
Xkdj
Capital Allocation
Zjwmnmtz

Bulls Say, Bears Say

Bulls

With autonomy from its former parent, Kenvue can allocate resources to best fit its needs and grow the business.

Bears

As rising input costs put pressure on Kenvue to hike prices, consumers could start to seek cheaper options or private label offerings, hurting Kenvue’s volumes.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if KVUE is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$20.45
Day Range
$20.37–20.61
52-Week Range
$17.82–27.80
Bid/Ask
$20.45 / $20.96
Market Cap
$39.33 Bil
Volume/Avg
14.4 Mil / 17.1 Mil

Key Statistics

Price/Earnings (Normalized)
16.10
Price/Sales
2.46
Dividend Yield (Trailing)
3.89%
Dividend Yield (Forward)
3.89%
Total Yield
3.89%

Company Profile

Kenvue is the world’s largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson’s consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women’s health. Its portfolio includes a wide array of some of the most well-known brands in the space, including Tylenol, Listerine, Johnson’s, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and ever-changing consumer preferences, many of Kenvue’s brands are the global leader in their respective segment thanks to their strong brand power.
Sector
Consumer Defensive
Industry
Household & Personal Products
Stock Style Box
Mid Core
Total Number of Employees
22,000
Website
https://www.kenvue.com

Competitors

Valuation

View More
Metric
KVUE
PG
UL
Price/Earnings (Normalized)
 16.1025.2718.04
Price/Book Value
 3.707.916.58
Price/Sales
 2.464.862.07
Price/Cash Flow
 16.5020.1315.98
Price/Earnings
KVUE
PG
UL

Financial Strength

Metric
KVUE
PG
UL
Quick Ratio
 0.640.400.51
Current Ratio
 0.990.640.76
Interest Coverage
 5.2020.669.28
Quick Ratio
KVUE
PG
UL

Profitability

Metric
KVUE
PG
UL
Return on Assets (Normalized)
 6.14%13.82%8.54%
Return on Equity (Normalized)
 12.16%35.61%35.06%
Return on Invested Capital (Normalized)
 9.26%20.62%13.94%
Return on Assets
KVUE
PG
UL
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Household & Personal Products Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
PG
Procter & Gamble CoTrlryvvzlVsvz$391.9 Bil
UL
Unilever PLC ADRHdqhhzxLmcp$132.4 Bil
CL
Colgate-Palmolive CoMbnbyhfdTnwrn$77.2 Bil
EL
The Estee Lauder Companies Inc Class AHsbgcfdQzt$46.4 Bil
KMB
Kimberly-Clark CorpGzqddpxdpFrvstcr$45.8 Bil
RBGLY
Reckitt Benckiser Group PLC ADRBqyxfwtcnScjfn$40.3 Bil
CHD
Church & Dwight Co IncGbyxjtgjNzcq$26.1 Bil
CLX
Clorox CoLzjqmsbcyKlfkq$17.4 Bil
COTY
Coty Inc Class AXpzfhWyyts$9.5 Bil

Sponsor Center